临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Dexamethasone Acetate
中文名称:醋酸地塞米松
CAS号:1177-87-3
分子式: C24H31FO6 分子量: 434.50
产品形式: free base
研发状态: Not yet recruiting
研发用途: Relapsed and/or Refractory Multiple Myeloma
研究机构: Adriana Rossi; Icahn School of Medicine at Mount Sinai
研发日期: June 3 2024
研发阶段: Phase 1 : Phase 2
Dexamethasone (NSC 39471,Dexamethasone 21-acetate) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects.
Azithromycin Dihydrate
中文名称:阿奇霉素二水合物
CAS号:117772-70-0
分子式: C38H72N2O12.2H2O 分子量: 785.02
产品形式: free base
研发状态: Not yet recruiting
研发用途: Infectious Disease; Therapeutics
研究机构: Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit; Mahidol Oxford Tropical Medicine Research Unit
研发日期: March 20 2024
研发阶段: Phase 2 : Phase 3
Azithromycin Dihydrate(CP-62993 dihydrate) is an acid stable orally administered macrolide antimicrobial drug, structurally related to erythromycin.
Vadimezan (ASA404)
中文名称:2,5-己酮可可碱
CAS号:117570-53-3
分子式: C17H14O4 分子量: 282.29
产品形式: free base
研发状态: Completed
研发用途: Refractory Tumors
研究机构: Antisoma Research
研发日期: May-03
研发阶段: Phase 1
Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.
BMS-794833
中文名称:N-[4-[(2-氨基-3-氯-4-吡啶)氧基]-3-氟苯基]-5-(4-氟苯基)-1,4-二氢-4-氧代-3-吡啶羧酰胺
CAS号:1174046-72-0
分子式: C23H15ClF2N4O3 分子量: 468.84
产品形式: free base
研发状态: Withdrawn
研发用途: Advanced Solid Tumors
研究机构: Bristol-Myers Squibb
研发日期: Jan-09
研发阶段: Phase 1
BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.
AZD2461
中文名称: 4-[4-氟-3-[(4-甲氧基哌啶-1-基)羰基]苄基]酞嗪-1(2H)-酮
CAS号:1174043-16-3
分子式: C22H22FN3O3 分子量: 395.43
产品形式: free base
研发状态: Completed
研发用途: Refractory Solid Tumors; Cancer Tumor
研究机构: AstraZeneca
研发日期: Nov-10
研发阶段: Phase 1
AZD2461 is a novel PARP inhibitor with low affinity for Pgp than Olaparib. Phase 1.
Relebactam
中文名称:瑞来巴坦
CAS号:1174018-99-5
分子式: C12H20N4O6S 分子量: 348.38
产品形式: free base
研发状态: Recruiting
研发用途: Cystic Fibrosis; Pneumonia Bacterial
研究机构: Hartford Hospital; Merck Sharp & Dohme LLC; Q2 Solutions; Connecticut Children''s Medical Center; St. Christopher''s Hospital for Children; University of Texas Southwestern Medical Center; University of Pittsburgh Medical Center; Indiana University Health Methodist Hospital; James Whitcomb Riley Hospital for Children
研发日期: January 3 2023
研发阶段: Phase 4
Relebactam (MK-7655) is a potent inhibitor against KPC-2, class A and class C (AmpC) β-lactamases.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
